Death (all causes) · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in all‐cause death Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in cardiovascular death Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in doubling of SCr Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal stroke Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors (ACEi) alone changes micro‐ to macroalbuminuria Median compared with ACEi plus angiotensin receptor blockers (very low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Death (any cause) (median · people with diabetes and kidney disease
1 finding from 1 review
Cardiovascular death4 Median · people with diabetes and kidney disease
1 finding from 1 review
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal stroke · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to macroalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to normoalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Decline in residual kidney function (12 months) · patients receiving PD
1 finding from 1 review
Anuria · patients receiving PD
Angiotensin‐converting enzyme inhibitors (ACEi) probably leads to lower anuria compared with conventional therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients receiving PD
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in mortality compared with conventional therapy (moderate certainty).
1 finding from 1 review
Cardiac events · patients receiving PD
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events compared with conventional therapy (moderate certainty).
1 finding from 1 review
Cardiac events (fatal) · patients receiving PD
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (fatal) compared with conventional therapy (moderate certainty).
1 finding from 1 review
Cardiac events (non fatal) · patients receiving PD
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (non fatal) compared with conventional therapy (moderate certainty).
1 finding from 1 review